Psychiatric Bulletin (2005) 29: 302-304. doi: 10.1192/pb.29.8.302
© 2005 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ahmer, S.
Right arrow Articles by Faruqui, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ahmer, S.
Right arrow Articles by Faruqui, R.
Psychiatric Bulletin (2005) 29: 302-304
© 2005 The Royal College of Psychiatrists

Conflict of interest in psychiatry

Syed Ahmer, Specialist Registrar in General Adult Psychiatry

Tony Hillis Wing, West London Mental Health NHS Trust, Uxbridge Road, Southall, Middlesex UB1 3EU, e-mail: ahmer{at}doctors.org.uk

Pradeep Arya, Specialist Registrar in General Adult Psychiatry

St Mary’s Higher Training Scheme in Psychiatry, St Charles Hospital

Duncan Anderson, Specialist Registrar in Forensic Psychiatry

Three Bridges Medium Secure Unit, West London Mental Health NHS Trust

Rafey Faruqui, Specialist Registrar in General Adult Psychiatry

West London Mental Health NHS Trust and Honorary Research Fellow, Imperial College London

AIMS AND METHOD

To study the association between study support and outcome in randomised controlled trials (RCTs) of psychotropic drugs, we reviewed all RCTs published in four psychiatry journals over a 5-year period. Chi-squared tests were used to analyse the association between RCT support and outcome, and logistic regression to determine which variable best predicted outcome.

RESULTS

A significantly higher proportion of manufacturer-supported RCTs (125/138, 91%, 95% CI 88-93) had a positive outcome than non-manufacturer-supported RCTs (39/50, 78%, 95% CI 72-84; P=0.02). Having an employee author almost guaranteed a positive outcome (56/58, 97%, 95%CI94 -99).

CLINICAL IMPLICATIONS

Outcomes of drug RCTs have a significant association with support by the manufacturer of the experimental drug. Systematic reviews and meta-analyses based on these RCTs may be biased in favour of newer drugs.




This article has been cited by other articles:


Home page
 Br. J. PsychiatryHome page
S. Hamer and P. M. Haddad
Adverse effects of antipsychotics as outcome measures
The British Journal of Psychiatry, August 1, 2007; 191(50): s64 - s70.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
P. M. Haddad and S. Dursun
Selecting antipsychotics in schizophrenia: lessons from CATIE
J Psychopharmacol, May 1, 2006; 20(3): 332 - 334.
[PDF]